Tissue-derived macromolecules and markers of inflammation in serum in early rheumatoid arthritis: Relationship to development of joint destruction in hands and feet

British Journal of Rheumatology

Volumn 36, Issue 11, 1997, Pages 1161-1165

  Fex, E ^a,b   Eberhardt, K ^a   Saxne, T ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bone sialoprotein; Cartilage oligomeric matrix protein; Hyaluronan; Joint destruction; Rheumatoid arthritis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; HYALURONIC ACID; MATRIX PROTEIN; SIALOPROTEIN;

ARTICLE; BLOOD LEVEL; DISEASE COURSE; ERYTHROCYTE SEDIMENTATION RATE; FOOT DISEASE; HAND DISEASE; HUMAN; HUMAN TISSUE; JOINT DESTRUCTION; PATIENT; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; RHEUMATOID ARTHRITIS;

EID: 0031408673     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/36.11.1161     Document Type: Article

References (26)

1. Fex E, Jonsson K, Johnson U, Eberhardt K. Development of radiographic damage during the first 5-6 years of rheumatoid arthritis. A prospective follow up study of a Swedish cohort. Br J Reumatol 1996;35:1106-15.
2. van der Heijde DMFM, van Riel PLCM, van Rijswijk MH, van de Putte LBA. Influence of prognostic features on the final outcome in rheumatoid arthritis: A review of the literature. Semin Arthritis Rheum 1988;17:284-92.
3. Wollheim FA, Eberhardt KB. The search for laboratory measures of outcome in rheumatoid arthritis. Baillière's Clin Rheumatol 1992;6:69-93.
4. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-89.
5. Klareskog L, Rönnelid J, Holm G. Immunopathogenesis and immunotherapy in rheumatoid arthritis: an area in transition. J Intern Med 1995;238:191-206.
6. Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
7. Eberhardt KB, Rydgren LC, Petersson H, Wollheim FA. Early rheumatoid arthritis - onset, course, and outcome over 2 years. Rheumatol Int 1990;10:135-42.
8. van Leeuwen MA, van Rijswijk MH. Acute phase proteins in monitoring of inflammatory disorders. Baillière's Clin Rheumatol 1994;8:531-52.
9. Möttönen TT. Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann Rheum Dis 1988;47:648-53.
10. van der Heijde DM, van Leeuwen MA, van Riel PL et al. Biannual radiographic assessments of hands and feet in a three-year prospective follow-up of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35:126-34.
11. Amos RC, Constable TJ, Crockson RA, Crockson AP, McConkey B. Rheumatoid arthritis: relation of serum C-reactive protein and erythrocyte sedimentation rate to radiographic changes. Br Med J 1977;2:195-7.
12. Dawes PT, Fowler PD, Clarke S et al. Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression. Br J Rheumatol 1986;25:44-9.
13. van Leeuwen MA, van Rijswijk MH, van der Heijde DMFM et al. The acute phase response in relation to radiographic progression in early rheumatoid arthritis. Br J Rheumatol 1993;32(suppl. 3):9-13.
14. van Leeuwen MA, van Rijswijk MH, Sluiter WJ et al. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol 1997;24:20-7.
15. Heinegård D, Saxne T. Matrix proteins: Potentials as body fluid markers of changes in the metabolism of cartilage and bone in arthritis. J Rheumatol 1995;22(suppl. 43):71-4.
16. Heinegård D, Oldberg A. Glycosylated matrix proteins. In: Royce PM, Steinmann B, eds. Connective tissue and its heritable disorders. New York: Wiley-Liss, 1993: 189-209.
17. Saxne T, Heinegård D. Cartilage oligomeric matrix protein: A novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 1992;31:583-91.
18. Saxne T, Zunino L, Heinegård D. Increased release of bone sialoprotein into synovial fluid reflects tissue destruction in rheumatoid arthritis. Arthritis Rheum 1995;1:82-90.
19. Laurent TC, Frazer JRE, Laurent UBG, Engström-Laurent A. Hyaluronan in inflammatory joint disease. Acta Orthop Scand 1995;66(suppl. 266): 116-20.
20. Forslind K, Eberhardt K, Jonsson A, Saxne T. Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis. Br J Rheumatol 1992;31:593-8.
21. Månsson B, Carey D, Alini M et al. Cartilage and bone metabolism in rheumatoid arthritis. Difference between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995;95:1071-7.
22. Paimela L, Heiskanen A, Kurki P, Helve T, Leirisalo-Repo M. Serum hyaluronate level as a predictor of radiologic progression in early rheumatoid arthritis. Arthritis Rheum 1991;7:815-21.
23. Ropes MW, Bennet GA, Cobb S, Jacox R, Jessar RA. Diagnostic criteria for rheumatoid arthritis. Ann Rheum Dis 1959;18:49-53.
24. Larsen A, Dale K. Standardized radiological evaluation of rheumatoid arthritis in therapeutic trials. In: Dumonde DC, Jasani MK, eds. The recognition of anti-rheumatic drugs. Lancaster: MTP Press, 1978: 285-92.
25. Fries JF, Bloch DA, Sharp JT et al. Assessment of radiologic progression in rheumatoid arthritis. Arthritis Rheum 1986;29:1-9.
26. Brandt R, Hedlöf E, Åsman I, Bucht A, Tenblad A. A convenient radiometric assay for hyaluronan. Acta Otolaryngol Suppl. 1987; 442:31-5.